Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy
Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiat...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522002672 |
| _version_ | 1798031331962126336 |
|---|---|
| author | Xiaohong Cen Baoqu Wang Yuqing Liang Yanlin Chen Yu Xiao Shaohua Du Kutty Selva Nandakumar Hang Yin Shuwen Liu Kui Cheng |
| author_facet | Xiaohong Cen Baoqu Wang Yuqing Liang Yanlin Chen Yu Xiao Shaohua Du Kutty Selva Nandakumar Hang Yin Shuwen Liu Kui Cheng |
| author_sort | Xiaohong Cen |
| collection | DOAJ |
| description | Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiation and deterioration. However, the contribution of TLR3 to atherosclerosis remains unclear. Herein, we identified the clinical relevance of TLR3 upregulation and disease processes in human atherosclerosis. Besides, activation of TLR3 also directly led to significant expression of atherogenic chemokines and adhesion molecules. Conversely, silencing TLR3 inhibited the uptake of oxLDL by macrophages and significantly reduced foam cell formation. Given the aberrance in TLR3 functions on atherosclerosis progression, we hypothesized that TLR3 could serve as novel target for clinical atherosclerosis therapy. Therefore, we developed the novel ellipticine derivative SMU-CX24, which specifically inhibited TLR3 (IC50 = 18.87 ± 2.21 nmol/L). In vivo, atherosclerotic burden was alleviated in Western diet fed ApoE−/− mice in response to SMU-CX24 treatment, accompanying notable reductions in TLR3 expression and inflammation infiltration within atherosclerotic lesion. Thus, for the first time, we revealed that pharmacological downregulation of TLR3 with specific inhibitor regenerated inflammatory environment to counteract atherosclerosis progression, thereby proposing a new strategy and probe for atherosclerosis therapy. |
| first_indexed | 2024-04-11T19:55:42Z |
| format | Article |
| id | doaj.art-49d7fa9edbb543ae8d8c9e23b8a48367 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-04-11T19:55:42Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-49d7fa9edbb543ae8d8c9e23b8a483672022-12-22T04:06:03ZengElsevierActa Pharmaceutica Sinica B2211-38352022-09-0112936673681Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapyXiaohong Cen0Baoqu Wang1Yuqing Liang2Yanlin Chen3Yu Xiao4Shaohua Du5Kutty Selva Nandakumar6Hang Yin7Shuwen Liu8Kui Cheng9Guangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaGuangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaGuangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaGuangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaGuangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaDepartment of Musculoskeletal Oncology, the Third Affiliated Hospital of Southern Medical University, Guangzhou 510642, ChinaGuangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaSchool of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University, Beijing 100084, China; Corresponding authors.Guangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Corresponding authors.Guangdong Provincial Key Laboratory of New Drug Screening and State Key Laboratory of Organ Failure Research, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Department of Musculoskeletal Oncology, the Third Affiliated Hospital of Southern Medical University, Guangzhou 510642, China; Corresponding authors.Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiation and deterioration. However, the contribution of TLR3 to atherosclerosis remains unclear. Herein, we identified the clinical relevance of TLR3 upregulation and disease processes in human atherosclerosis. Besides, activation of TLR3 also directly led to significant expression of atherogenic chemokines and adhesion molecules. Conversely, silencing TLR3 inhibited the uptake of oxLDL by macrophages and significantly reduced foam cell formation. Given the aberrance in TLR3 functions on atherosclerosis progression, we hypothesized that TLR3 could serve as novel target for clinical atherosclerosis therapy. Therefore, we developed the novel ellipticine derivative SMU-CX24, which specifically inhibited TLR3 (IC50 = 18.87 ± 2.21 nmol/L). In vivo, atherosclerotic burden was alleviated in Western diet fed ApoE−/− mice in response to SMU-CX24 treatment, accompanying notable reductions in TLR3 expression and inflammation infiltration within atherosclerotic lesion. Thus, for the first time, we revealed that pharmacological downregulation of TLR3 with specific inhibitor regenerated inflammatory environment to counteract atherosclerosis progression, thereby proposing a new strategy and probe for atherosclerosis therapy.http://www.sciencedirect.com/science/article/pii/S2211383522002672Toll-like receptor 3AtherosclerosisSmall moleculeInflammationMacrophage |
| spellingShingle | Xiaohong Cen Baoqu Wang Yuqing Liang Yanlin Chen Yu Xiao Shaohua Du Kutty Selva Nandakumar Hang Yin Shuwen Liu Kui Cheng Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy Acta Pharmaceutica Sinica B Toll-like receptor 3 Atherosclerosis Small molecule Inflammation Macrophage |
| title | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
| title_full | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
| title_fullStr | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
| title_full_unstemmed | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
| title_short | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
| title_sort | small molecule smu cx24 targeting toll like receptor 3 counteracts inflammation a novel approach to atherosclerosis therapy |
| topic | Toll-like receptor 3 Atherosclerosis Small molecule Inflammation Macrophage |
| url | http://www.sciencedirect.com/science/article/pii/S2211383522002672 |
| work_keys_str_mv | AT xiaohongcen smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT baoquwang smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT yuqingliang smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT yanlinchen smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT yuxiao smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT shaohuadu smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT kuttyselvanandakumar smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT hangyin smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT shuwenliu smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT kuicheng smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy |